Q-omics provides the consensus-scored SNCG profile across patient tissues and cancer cell-line models. SNCG expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNCG is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SNCG protein abundance shows 25,696 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where SNCG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNCG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNCG survival associations across molecular data types. SNCG RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNCG RNA expression–survival associations across cancer types. High SNCG expression shows unfavorable associations in UVM, STAD and KIRP, but favorable associations in ACC, MESO and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNCG RNA expression.
This table summarizes SNCG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNCG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNCG shows lower tumor expression in COAD, LUSC, UCEC and BRCA and higher tumor expression in LIHC and KIRC. The COAD box plot shows higher SNCG RNA expression in normal versus tumor tissue (log2 FC = −1.732, t-test p < 0.001).
This table shows molecular features associated with SNCG in patient tissues and cancer cell lines. In patient samples, SNCG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNCG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and URINARY_TRACT.
